2025 Expert Speaker Faculty

Aaron Koenig - Chief Medical Officer at Delix Therapeutics, Neuropsychiatric Drug Development Conference

Aaron Koenig

Chief Medical Officer

Delix Therapeutics

Abhi Pratap - Executive Director, Global Evidence Lead, Neuropsychiatric Drug Development Summit

Abhishek Pratap

Executive Director - Global Evidence Lead

Boehringer Ingelheim

Alastair Brown - Senior vice president & head of translational science at Nxera Pharma, Neuropsychiatric Drug Development Conference

Alastair Brown

Senior Vice President - Translational Medicine

Nxera Pharma

Alex Goddard - Director, McQuade Center for Strategic Research and Development at Otsuka, Neuropsychiatric Drug Development Summit

Alex Goddard

Director, McQuade Center for Strategic Research and Development

Otsuka

Allison House Gecewicz - Senior Vice President & Head of Clinical Operations of Cybin, Neuropsychiatric Drug Development Summit

Allison House-Gecewicz

Senior Vice President & Head of Clinical Operations

Cybin

Amy Kruse - Chief Investment Officer at Satori Capital, Neuropsychiatric & Psychedelic Drug Development Conference

Amy Kruse

GP Satori Neuro

Satori Capital

Chirs Weyrer - Principal at Vida Ventures, Neuropsychiatric & Psychedelic Drug Development Conference

Chris Weyrer

Principal

Vida Ventures

Christopher Ocampo - Group Medical Director, Psychiatry of AbbVie, Neuropsychiatric Drug Development Summit

Christopher Ocampo

Group Medical Director, Psychiatry

Abbvie

Colin Sauder - Chief Scientific Officer at Karuna Therapeutics, Neuropsychiatric & Psychedelic Drug Development Summit

Colin Sauder

Chief Scientific Officer

Adams Clinical (formerly Bristol Myers Squibb / Karuna Therapeutics)

Connor Maltby, Team Leader - Biomarker/Cell Culture, Ulysses Neuroscience

Connor Maltby

Head of Translational Medicine

Ulysses Neuroscience

Dan Bonner -Co-Founder & Senior Vice President at Seaport Therapeutics, Neuropsychiatric & Psychedelic Drug Development Summit

Dan Bonner

Co-founder & Senior Vice President - Platform

Seaport Therapeutics

Dan Jeffries

Principal

Negev Labs

David Olson - Chief Innovation Officer at Delix Therapeutics, Neuropsychiatric & Psychedelic Drug Development Conference

David Olson

Chief Innovation Officer

Delix Therapeutics

David Ruhl- Principal Scientist, Translational Science of Neurocrine Bioscience, Neuropsychiatric Drug Development Summit

David Ruhl

Principal Scientist - Translational

Neurocrine Biosciences

Douglas Turk

Director, Bpt Laboratory Operations

Eurofins

Drew Elias - Director, Global Regulatory Lead of Neuroscience at Johnson & Johnson, Neuropsychiatric Drug Development Forum

Drew Elias

Director, Global Regulatory Lead, Neuroscience

Johnson & Johnson

Enya Paschen, Team Leader, Behavioural Pharmacology/EEG, Ulysses Neuroscience

Enya Paschen

Head of Preclinical Neuropharmacology

Ulysses Neuroscience

Gabriel Jacobs, Director - Research & Psychiatry, Center For Human Drug Research

Gabriel Jacobs

Director - Research & Psychiatry

Center For Human Drug Research

Heramb Chadchankar - Senior director & head of translational science at Kynexis Therapeutics, Neuroscience and Psychedelic Drug Development Conference

Heramb Chadchankar

Senior Director & Head of Translational Science

Kynexis Therapeutics

Jackie Von Salm - Co-Founder & Chief Scientific Officer at Psilera, Neuropsychiatric Drug Development Forum

Jackie von Salm

Co-Founder & Chief Scientific Officer

Psilera

Jacob Jacobsen - Chief Executive Officer of Evecxia Therapeutics, Neuropsychiatric Drug Development Conference

Jacob Jacobsen

Chief Executive Officer

Evecxia Therapeutics

Jake Donoghue

Chief Executive Officer & Co-Founder

Beacon Biosignals

James Cronican - Head of Translational Medicine & Clinical Pharmacology for Neuroscience & Mental Health at Boehringer Ingelheim, Neuropsychiatric Drug Development Forum

James Cronican

Head of Translational Medicine & Clinical Pharmacology Neuroscience & Mental Health

Boehringer Ingelheim

Jamileh Jemison - Medical Director of Clinical Development at MindMed, Neuropsychiatric Drug Development Conference

Jamileh Jemison

Medical Director, Clinical Development

MindMed

Janet Nicholson - Global Asset Lead, CNS Diseases, Translational Medicine at Boehringer Ingelheim, Neuropsychiatric & Psychedelic Drug Development Forum

Janet Nicholson

Global Lead - Asset , CNS Diseases & Translational Medicine

Boehringer Ingelheim

Jessica Ash - Director of Digital Health & Research at Otsuka, Neuropsychiatric & Psychedelic Drug Development Forum

Jessica Ash

Director - Digital Health, Research & Development

Otsuka

James Gilligan - President & Chief Executive Officer at Tryp Therapeutics, Neuropsychiatric & Psychedelic Drug Development Forum

JGilligan Gilligan

CSO

Tryp Therapeutics

Johan Luthman - Executive Vice President & Head of Research at Lundbeck, Neuropsychiatric & Psychedelic Drug Development Conference

Johan Luthman

Executive Vice President & Head of R&D

Lundbeck

John Huxter, Associate Director and Head of Rodent EEG, Transpharmation™

John Huxter

Associate Director and Head of Rodent EEG

Transpharmation™

Jonathan Nassi - Senior Director Translational Science & Head of Discovery Lab at Inscopix, Neuropsychiatric Drug Development Conference

Jonathan Nassi

Senior Director & Head of the Inscopix Discovery Lab

Inscopix

Kevin Spencer - Associate Professor of Psychiatry at Harvard University, Neuropsychiatric & Psychedelic Drug Development Summit

Kevin Spencer

Assoc Professor

Harvard University

Krishna Vadodaria - Director at Engrail Therapeutics, Neuropsychiatric & Psychedelic Drug Development Summit

Krishna Vadodaria

Director, Neurobiology

Engrail Therapeutics

Liam Scott - Senior Director of Translational Sciences at Neumora, Neuropsychiatric Drug Development Summit

Liam Scott

Senior Director

Neumora

Matt Harlin - Senior Director, Discovery Research, Early Phase & Translational Medicine at Otsuka, Neuropsychiatric Drug Development Summit

Matt Harlin

Senior Director

Otsuka

Matt Harlin - Senior Group Leader at Harvard and MIT, Neuropsychiatric Drug Development Summit

Matthew Johnson

Senior Group Leader

The Broad Institute of MIT & Harvard

Matt Kuntz - Vice President & Global Head of Regulatory Affairs at AbbVie, Neuropsychiatric Drug Development Summit

Matthew Kuntz

Neuroscience Vice President, Global Regulatory Affairs

Abbvie

Michael Bowen - Chief Scientific Officer of Kinoxis Therapeutics, Neuropsychiatric Drug Development Conference

Michael bowen

CSO

Kinoxis Therapeutics

Namik Kirlic

Director, Clinical Care Research

Compass Pathways

Nanco Hefting, Chief Specialist, Lundbeck

Nanco Hefting

Chief Specialist

Lundbeck

Natalie Sacks - Venture Partner at Novo Holdings, Neuropsychiatric Drug Development Conference

Natalie Sacks

Venture

Novo Holdings

Nurulain Zaveri - President and Chief Scientific Officer of Astraea Therapeutics, Neuropsychiatric Drug Development Summit

Nurulain Zaveri

President and CSO

Astraea Therapeutics

Odette Hauke - Regulatory Affairs Consultant for Neuropsychiatric Drug Development

Odette Hauke

Regulatory Affairs Consultant

Independent

Sam Benezra - Senior Scientist, Neural Circuits Group at Biogen, Neuropsychiatric & Psychedelic Drug Development

Sam Benezra

Senior Scientist, Neural Circuits Group

Biogen

Shlomi Raz

Partner

Negev Labs

Shobi Ahmed - Chief Executive Officer of Sama Therapeutics, Neuropsychiatric Drug Development Summit

Shobi Ahmed

Founder & Chief Executive Officer

Sama Therapeutics

Silke Miller - Scientist of Translational Sciences at Johnson & Johnson, Neuropsychiatric & Psychedelic Drug Development

Silke Miller

Director Clinical Science

Johnson & Johnson

Snezana Milanovic - Senior Director of Clinical Development at Neumora, Neuropsychiatric & Psychedelic Drug Development

Snezana Milanovic

Senior Medical Director, Clinical Development

Xenon Pharmaceuticals

Steve Brennan -Chief Medical Officer at Karuna Therapeutics, Neuropsychiatric & Psychedelic Drug Development

Steve Brannan

Former Chief Medical Officer

Karuna Therapeutics

Steve Hyman - Professor of Stem Cell & Regenerative Biology at Harvard University, Psychedelic Drug Development Conference

Steven Hyman

Professor of Stem Cell & Regenerative Biology

Harvard University

Trent Fowler - Associate Director, Bioanlaysis, Genomics & Biomarker Research Early Phase Translational Medicine at Otsuka, Psychedelic Drug Development Summit

Trent Fowler

Associate Director

Otsuka

William Horan - Clinical Science Program Lead Neuropsychiatry at Bristol Myers Squibb, Psychedelic Drug Development Forum

William Horan

Former Clinical Science Program Lead, Neuropsychiatry

Bristol Myers Squibb

Willie Earley, Head of Clinical Development, Intra-Cellular Therapies

Willie Earley

Head of Clinical Development

Intra-Cellular Therapies

Zhanyan Fu - Associate Director of Broad Institute of MIT and Harvard, Neuroscience and Psychedelic Drug Development Conference

Zhanyan Fu

Associate Director

Broad Institute of MIT & Harvard

Explore the 2025 Agenda
Register Interest
Partner With Us in 2026